PreveCeutical Medical (FRA:18H0) Moat Score: 2/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PreveCeutical Medical Moat Score?

PreveCeutical Medical FRA:18H0 Moat Score is 2 as of Jul. 16, 2026. The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, PreveCeutical Medical ranks better than 58.31% on this metric.

PreveCeutical Medical has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

PreveCeutical Medical has No Moat: PreveCeutical Medical lacks significant market share, brand strength, or proprietary technology. The company operates in a highly competitive biotech sector with minimal regulatory barriers or customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PreveCeutical Medical might have No Moat - Very weak/transient advantages.

PreveCeutical Medical  (FRA:18H0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PreveCeutical Medical Moat Score Related Terms

FRA:18H0 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, PreveCeutical Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PreveCeutical Medical Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PreveCeutical Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where PreveCeutical Medical's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
PreveCeutical Medical (FRA:18H0) has a Moat Score of 2 as of Jul. 16, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PreveCeutical Medical ranks #582 out of 1396 companies in the Biotechnology industry, placing it in the top 41.7%.
Is PreveCeutical Medical's Moat Score too high?
PreveCeutical Medical's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. PreveCeutical Medical's value of 2 is 0% at this industry median. Based on the distribution chart, PreveCeutical Medical ranks #582 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint.
How does PreveCeutical Medical's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PreveCeutical Medical ranks #582 out of 1396 companies for Moat Score. This puts PreveCeutical Medical in the upper half of its industry. The industry median Moat Score is 2.00. PreveCeutical Medical's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PreveCeutical Medical's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PreveCeutical Medical's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PreveCeutical Medical stock overvalued right now?
PreveCeutical Medical (FRA:18H0) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PreveCeutical Medical (FRA:18H0), the current Moat Score is 2 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PreveCeutical Medical Business Description

Other Exchanges PRVCF:USAPREV:Canada
Address 550 Burrard Street, Bentall 5, Suite 2501, Vancouver, BC, CAN, V6C 2B5
PreveCeutical Medical Inc is a health sciences company. The principal business activity of the company is the development of options for preventive and curative therapies utilizing organic and nature-identical products. The company is engaged in licensing, branding, and marketing nutraceutical and wellness products.